SFA
ALNY icon

Sequoia Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sequoia Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
4,347
-213
-5% -$64.2K 0.01% 823
2026
Q1 		$1.51M Buy
4,560
+348
+8% +$118K 0.01% 713
2025
Q4 		$1.67M Sell
4,212
-94
-2% -$41.6K 0.01% 649
2025
Q3 		$1.96M Buy
4,306
+389
+10% +$158K 0.01% 525
2025
Q2 		$1.28M Buy
3,917
+522
+15% +$144K 0.01% 603
2025
Q1 		$917K Buy
3,395
+99
+3% +$25.4K 0.01% 648
2024
Q4 		$776K Buy
3,296
+167
+5% +$43.9K 0.01% 660
2024
Q3 		$861K Sell
3,129
-179
-5% -$46.6K 0.01% 590
2024
Q2 		$804K Buy
3,308
+398
+14% +$62.8K 0.01% 542
2024
Q1 		$435K Sell
2,910
-4,804
-62% -$801K 0.01% 735
2023
Q4 		$1.48M Buy
7,714
+4,911
+175% +$837K 0.02% 424
2023
Q3 		$496K Sell
2,803
-148
-5% -$28.2K 0.01% 528
2023
Q2 		$561K Buy
+2,951
New +$585K 0.01% 493
2023
Q1 		– Sell
-934
Closed -$222K – 842
2022
Q4 		$222K Buy
+934
New +$199K 0.01% 701

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sequoia Financial Advisors's ALNY Position: Q2 2026 in Review

Sequoia Financial Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.7% in Q2 2026, selling an estimated $64.2K and leaving 4,347 shares worth $1.31M. The position accounts for 0.01% of the portfolio, ranked #823.

Sequoia Financial Advisors first reported a position in ALNY in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.96M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sequoia Financial Advisors held 4,347 shares of Alnylam Pharmaceuticals worth $1.31M as of Q2 2026.
  • Sequoia Financial Advisors sold 213 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $64.2K.
  • Alnylam Pharmaceuticals made up 0.01% of Sequoia Financial Advisors's portfolio in Q2 2026, its #823 holding.
  • Sequoia Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Sequoia Financial Advisors's Alnylam Pharmaceuticals position peaked at $1.96M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sequoia Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.